BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Morvillo C, Vinci K, Hedenschoug L, Mancini L, Mize C, Tugg K, Stein S. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses. Gastroenterology Nursing 2020;43:E159-71. [DOI: 10.1097/sga.0000000000000523] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gole B, Potočnik U. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis. Cells 2019;8:E515. [PMID: 31141991 DOI: 10.3390/cells8060515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Kienle P. Impact of Modern Drug Therapy on Surgery: Crohn's Disease. Visc Med 2018;34:422-5. [PMID: 30675486 DOI: 10.1159/000495127] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Xu Y, Sharma A, Chen Y, Zhou H. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others. Curr Pharmacol Rep 2019;5:115-30. [DOI: 10.1007/s40495-019-00180-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z, Sharma A, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol 2020;60:889-902. [PMID: 32026499 DOI: 10.1002/jcph.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Brusač E, Jeličić ML, Amidžić Klarić D, Nigović B, Turk N, Klarić I, Mornar A. Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods. Molecules 2019;24:E3469. [PMID: 31554326 DOI: 10.3390/molecules24193469] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
8 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
9 Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn's disease: ready to go? Expert Opin Investig Drugs 2022;31:145-61. [PMID: 35164629 DOI: 10.1080/13543784.2022.2032639] [Reference Citation Analysis]
10 Milanesi E, Dobre M, Manuc TE, Becheanu G, Tieranu CG, Ionescu EM, Manuc M. Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients. Drug Dev Res 2019;80:831-6. [PMID: 31322753 DOI: 10.1002/ddr.21566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Venkataraman B, Ojha S, Belur PD, Bhongade B, Raj V, Collin PD, Adrian TE, Subramanya SB. Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases. Phytother Res 2020;34:1530-49. [PMID: 32009281 DOI: 10.1002/ptr.6625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 He DG, Chen XJ, Huang JN, Chen JG, Lv MY, Huang TZ, Lan P, He XS. Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis. World J Gastrointest Oncol 2022; 14(1): 348-361 [DOI: 10.4251/wjgo.v14.i1.348] [Reference Citation Analysis]
13 Law CC, Koh D, Bao Y, Jairath V, Narula N; Cochrane IBD Group. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013256] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Ditto MC, Parisi S, Landolfi G, Borrelli R, Realmuto C, Finucci A, Caviglia GP, Ribaldone DG, Astegiano M, Zanetti A, Carrara G, Scirè CA, Antivalle M, Sarzi-Puttini P, Fusaro E. Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. RMD Open 2021;7:e001755. [PMID: 34489323 DOI: 10.1136/rmdopen-2021-001755] [Reference Citation Analysis]
15 Shukla T, Sands BE. Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0689-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
16 Adamina M, Fiorino G. At the crossroads of caution and intervention: anti-TNF therapy prior to elective CD surgery Authors' Reply to: "Anti-TNF therapy before intestinal surgery for Crohn's disease and the risks of postoperative complications". J Crohns Colitis 2021:jjab092. [PMID: 33999192 DOI: 10.1093/ecco-jcc/jjab092] [Reference Citation Analysis]
17 Restellini S, Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med 2021;10:1242. [PMID: 33802816 DOI: 10.3390/jcm10061242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hwang YJ, Nam SJ, Chun W, Kim SI, Park SC, Kang CD, Lee SJ. Anti-inflammatory effects of apocynin on dextran sulfate sodium-induced mouse colitis model. PLoS One 2019;14:e0217642. [PMID: 31141554 DOI: 10.1371/journal.pone.0217642] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
19 Marafini I, Sedda S, Dinallo V, Monteleone G. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opin Biol Ther 2019;19:1207-17. [PMID: 31373244 DOI: 10.1080/14712598.2019.1652267] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
20 Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis 2020;14:155-68. [PMID: 31742338 DOI: 10.1093/ecco-jcc/jjz187] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 38.5] [Reference Citation Analysis]
21 Liu W, Dong Z, Liu K, Lu Y, Wu W, Qi J, Chen Z. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. Int J Pharm 2021;600:120461. [PMID: 33711470 DOI: 10.1016/j.ijpharm.2021.120461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Geng B, Craig TJ. Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema. Ann Allergy Asthma Immunol 2021:S1081-1206(21)01162-5. [PMID: 34673223 DOI: 10.1016/j.anai.2021.10.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Salvador-Martín S, López-Cauce B, Nuñez O, Laserna-Mendieta EJ, García MI, Lobato E, Abarca-Zabalía J, Sanjurjo-Saez M, Lucendo AJ, Marín-Jiménez I, Menchén LA, López-Fernández LA. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. Pharmacol Res 2019;149:104478. [PMID: 31605784 DOI: 10.1016/j.phrs.2019.104478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Law CC, Bell C, Koh D, Bao Y, Jairath V, Narula N. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev 2020;10:CD013256. [PMID: 33098570 DOI: 10.1002/14651858.CD013256.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Mancini NL, Goudie L, Xu W, Sabouny R, Rajeev S, Wang A, Esquerre N, Al Rajabi A, Jayme TS, van Tilburg Bernandes E, Nasser Y, Ferraz JGP, Shutt T, Shearer J, McKay DM. Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis That Can Be Targeted to Lessen Disease. Cell Mol Gastroenterol Hepatol 2020;10:287-307. [PMID: 32298841 DOI: 10.1016/j.jcmgh.2020.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]